BioSpace News Archive

Program intended to facilitate CMC development for selected therapies with expedited clinical development timeframes to help patients get access sooner.

Theratechnologies Inc. today shared data demonstrating the cost-effectiveness of ibalizumab, a monoclonal antibody antiretroviral therapy (ART) commercialized in the U.S. under the trade name Trogarzo®, as an addition to optimized background regimens (OBR) in heavily treatment-experienced (HTE) people with HIV.

Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company’s cardiac myosin inhibitor programs and plans to build a specialty cardiology franchise today at its virtual Investor and Analyst Day, “New Horizons in Hypercontractility.”

Data from Qilu Pharmaceutical’s clinical trial of its novel bifunctional antibody, QL1706 (iparomlimab and tuvonralimab), will be unveiled during a mini oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress 2023.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced the appointment of Richard J. Daly as its new Chief Executive Officer effective January 1, 2024.

Lirum Therapeutics, Inc. announced today that Peter McDonald, the CEO of Lirum, will present at the 2023 ThinkEquity Conference on Thursday, October 19, 2023, at 2:00 PM ET.

NexImmune, Inc. today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA, being held November 1-5, 2023.

Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world’s premier pharmaceutical industry exhibitions.

Conference call with live webcast by Sequana Medical today at 03:00 pm CEST / 09:00 am EST

IRLAB Therapeutics IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-September 2023.